← FDA DRUG APPROVALS

FDA ANDA · ANDA040708

LIDOCAINE HYDROCHLORIDE

Sponsor: CHARTWELL MOLECULAR

APPLICATION
ANDA040708
TYPE
ANDA
ORIGINAL APPROVAL
2007-02-27
LATEST ACTION
2018-11-02
ROUTE
OROPHARYNGEAL, ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

LIDOCAINE HYDROCHLORIDE VISCOUSPrescription
LIDOCAINE HYDROCHLORIDE 2% · SOLUTION · ORAL

Approval history

2018-11-02Labeling · Supplement 7 · standardAP
2014-12-01Labeling · Supplement 6 · standardAP
2007-02-27OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →